key: cord-0950965-7gqjbldj
authors: Bocci, Matteo; Oudenaarden, Clara; Sàenz-Sardà, Xavier; Simrén, Joel; Edén, Arvid; Sjölund, Jonas; Möller, Christina; Gisslén, Magnus; Zetterberg, Henrik; Englund, Elisabet; Pietras, Kristian
title: Infection of brain pericytes underlying neuropathology of COVID-19 patients
date: 2021-05-25
journal: bioRxiv
DOI: 10.1101/2021.05.24.445532
sha: c451339175706001d615ff729f4907988b2c84d0
doc_id: 950965
cord_uid: 7gqjbldj

A wide range of neurological manifestations have been associated with the development of COVID-19 following SARS-CoV-2 infection. However, the etiology of the neurological symptomatology is still largely unexplored. Here, we used state-of-the-art multiplexed immunostaining of human brains (n = 6 COVID-19, median age = 69,5 years; and n = 7 control, median age = 68 years), and demonstrated that expression of the SARS-CoV-2 receptor ACE2 is restricted to a subset of neurovascular pericytes. Strikingly, neurological symptoms were exclusive to, and ubiquitous in, patients that exhibited moderate to high ACE2 expression in peri-vascular cells. Viral particles were identified in the vascular wall and paralleled by peri-vascular inflammation, as signified by T cell and macrophage infiltration. Furthermore, fibrinogen leakage indicated compromised integrity of the blood-brain barrier. Notably, cerebrospinal fluid from an additional 16 individuals (n = 8 COVID-19, median age = 67 years; and n = 8 control, median age = 69,5 years) exhibited significantly lower levels of the pericyte marker PDGFRβ in SARS-CoV-2-infected cases, indicative of disrupted pericyte homeostasis. We conclude that pericyte infection by SARS-CoV-2 underlies virus entry into the privileged central nervous system space, as well as neurological symptomatology due to peri-vascular inflammation and a locally compromised blood-brain barrier.

The clinical manifestations of coronavirus disease 2019 (COVID-19) infection primarily include respiratory symptoms, ranging from a mild cough to severe bilateral pneumonia 1, 2 .

However, SARS-CoV-2 bears an organotropism beyond the respiratory tract 3, 4 , with increasing testimony indicating the brain as an extrapulmonary target of SARS-CoV-2 5 . The involvement of the CNS encompasses a broad spectrum of neurological manifestations (including headache, fatigue, anosmia, ageusia, confusion, loss of consciousness), often representing an ulterior clinical morbidity that significantly contributes to COVID-19-related deaths [6] [7] [8] .

The main entry receptor for SARS-CoV-2 is reported to be the angiotensin-converting enzyme (ACE)2, which is a component of the renin-angiotensin system 9, 10 . To date there is still no conclusive evidence concerning the localization of ACE2 in the human CNS 3 , and the mechanism of SARS-CoV-2 infection in the brain remains a conundrum.

Here, using highly sensitive multiplexed immunohistochemistry (mIHC) of brain tissue from a series of confirmed COVID-19 patients and corresponding controls, we determined that ACE2 is exclusively expressed by brain pericytes in the subset of patients that also exhibited neurological symptoms. Moreover, spatial immunophenotyping revealed a localized perivascular inflammation in brain tissue from COVID-19 patients, paralleled by an impairment of the functionality of the vascular wall as indicated by loss of integrity of the blood-brain barrier (BBB). Finally, in the cerebrospinal fluid (CSF) of a cohort of COVID-19 patients with neurological involvement, levels of soluble PDGFRβ, a pericyte-specific marker in the brain, were significantly reduced compared with non-COVID-19 individuals, suggestive of SARS-CoV-2-related functional impairment of pericytes. Taken together, our findings highlight a previously unappreciated role for brain pericytes in acting as pioneers for SARS-CoV-2 entry into the CNS.

Patients Excessive brain tissues sampled from six COVID-19 autopsies and 7 non-COVID-19 cases were used to create formalin-fixed paraffin-embedded (FFPE) blocks (Supplementary Table   1 ). The use of these samples was approved by the Central Ethical Review Authority in Sweden (2020-02369, 2020-06582, and 2020-01771). Clinical data with details of neurologic symptoms or other signs of brain affection were sought in the referral documents or else in the Regional Medical Records database Melior, which was used also for the diagnostic work-up.

CSF from eight patients with neurological manifestations admitted to the Sahlgrenska University Hospital in Gothenburg, Sweden was included (Supplementary Table 2 ). Infection with SARS-CoV-2 was confirmed via rtPCR analysis. Age-and sex-matched non-COVID-19 controls were selected, consisting of patients who were examined because of clinical suspicion of neurological disease, but where no neurochemical evidence was found, based on clinical reference intervals. The use of these samples has been approved by the Regional Ethical Committee in Gothenburg.

Expression of Ace2 was investigated in publicly available single cell RNA sequencing (scRNA-seq) SMART-Seq2 RNA-seq libraries on FACS-sorted non-myeloid brain cells of seven mice (Tabula Muris) 11 , and in a database of murine vasculature 12, 13 .

Mouse whole brain and hippocampus SMART-seq data (gene expression aggregated per cluster, calculated as trimmed means) from the Allen Brain Atlas consortium was downloaded on 14 th October 2020 14, 15 . For expression of Pvalb and Sst neurons, the average was calculated of 13 and 40 cell clusters, respectively. Human ACE2 protein expression images were retrieved from the Human Protein Atlas initiative (Version 20.0) 16 .

Five μm-thick FFPE tissue sections were dewaxed and rehydrated through xylene and waterbased ethanol solutions. Heat-induced epitope retrieval was performed with a pressure cooker (2100 Antigen Retriever, BioVendor, Germany) in citrate or Tris-EDTA buffer (Agilent Dako, USA). Following endogenous peroxidase quenching (BLOXALL, Vector Laboratories, USA), tissues were incubated with CAS-block (Thermo Fisher Scientific, USA), 1 hour at room temperature (RT), and Ultra V block (Thermo Fisher Scientific, USA) for 5 minutes. Primary Table 3 ) diluted in CAS-block were applied for 30 minutes, followed by UltraVision ONE HRP polymer (Thermo Fisher Scientific, USA), 30 minutes, at RT. The ImmPACT DAB substrate (Vector Laboratories, USA) was applied. Tissues were counterstained with hematoxylin, dehydrated and mounted with Cytoseal 60 (Thermo Fisher Scientific, USA). Imaging was performed with an automated BX63 microscope connected to a DP-80 camera (Olympus, Japan).

FFPE sections used for IHC were subjected to multiplexed labelling following optimized protocols established in the lab. All reagents are from Akoya Biosciences (USA), including the Vectra Polaris scanner for imaging and the PhenoChart/InForm software. Following slide preparation, sections underwent staining cycles (Supplementary Table 4 ) -including blocking, primary antibody incubation, HRP tagging and labeling with OPAL-conjugated tyramide substrate-and a stripping procedure to remove unbound primary antibody/HRP. A counterstain with DAPI preceded the mounting with ProLong Diamond antifade (Thermo Fisher Scientific, USA).

The composite images were generated by removing inherent autofluorescence signal from an unstained section, as well as by comparing fluorescence intensities to those of a spectral library.

CSF sPDGFRβ concentration was measured by sandwich ELISA (Thermo Fisher Scientific, USA), as previously described 17 . Statistical Mann-Whitney U-test was performed using Prism (GraphPad Software, USA). The significance level was set at P < 0.05, two-sided.

The authors confirm that the data supporting the findings of this study are available within the article and its supplementary material.

The ACE2 receptor is expressed by pericytes in murine and human brain Expression of ACE2 in the brain has variably been reported in neurons, glial cells, and vascular cells [18] [19] [20] [21] [22] . Because of this ambiguity of localization, we started by exploring ACE2 expression in publicly available mRNA and protein datasets from murine and human brain. Mining of the Allen Mouse Brain Atlas of single cell transcriptomes demonstrated unique enrichment for Ace2 transcript in pericytes (Fig. 1A) . A similar compartmentalization was observed in the Tabula Muris 11 as well as in an scRNA-seq compendium of the murine brain vasculature 12, 13 (Supplementary Fig. 1A and B). In agreement with the transcriptional data, localization of the ACE2 protein by the Human Protein Atlas 16 was restricted to the peri-vascular compartment in a subset of blood vessels in human cerebral cortex ( Supplementary Fig. 1C ).

Next, we sought to investigate the expression of ACE2 in brain tissue of COVID-19 patients.

To this end, we obtained FFPE samples of multiple brain regions from six patients whose death was confirmed to be a consequence of SARS-CoV-2 infection (Supplementary Table 1 ). In the frontal cortex, moderate to high ACE2 immunoreactivity revealed a vascular pattern in a subset of blood vessels in five of the 13 cases (Fig. 1B) . Reassuringly, other brain regions showed equivalent distribution of ACE2, indicating that ACE2 was widely expressed in peri-vascular cells throughout the CNS (Fig. 1C) . Notably, ACE2 reactivity, which was confirmed with two different antibodies in positive control tissues from kidney ( Supplementary Fig. 1D ), appeared to be a patient-specific feature, since some cases did not show signal at all, or with very low frequency ( Fig. 1D and Supplementary Fig. 1E ). To conclusively validate which cell type harbored ACE2 expression, we performed mIHC on human brain tissue to simultaneously visualize ACE2, CD31 + endothelial cells, PDGFRβ + pericytes. ACE2 expression coincided with that of PDGFRβ, but not with CD31 staining (Fig. 1E and Supplementary Fig. 1F ).

immunoreactivity, with some cells bearing positivity solely for PDGFRβ, while others expressed both markers. Remarkably, the three COVID-19 patients that exhibited moderate to high peri-vascular ACE2 expression in the brain all presented with neurological symptoms, while all ACE2-negative patients remained free from such manifestations (Fig. 1D ).

Collectively, our data demonstrate that in the brain, ACE2 is exclusively expressed by pericytes in a manner that signifies development of neurological symptoms from COVID-19.

An increasing body of evidence converges on the inherent difficulty of detecting SARS-CoV-2 in the brain 23, 24 . To build on previous reports on the localization of SARS-CoV-2 in human brain tissue, we additionally analyzed brain samples from non-infected individuals to enable conclusions about the presence of the spike protein or the nucleocapsid protein of SARS-CoV/SARS-CoV-2 in the CNS with a higher certainty. For both viral components, positive areas in brain sections of COVID-19 patients exhibited comparable patterns with those shown in previous studies. 25 Notably, however, we demonstrated an analogous intensity and distribution of the viral proteins when we probed brain tissues from non-infected individuals ( Fig. 2A) . In order to unequivocally define our ability to visualize viral particles in human tissues, we gained access to placental tissue from a confirmed case of SARS-CoV-2 vertical transmission to serve as a positive control 26 . We also made use of the J2 antibody specifically designed to detect viral double-stranded (ds)RNA. In the placenta, a 7-plex mIHC panel Fig. 2B ). Finally, applying the now validated protocol for detection of viral dsRNA to brain sections, we identified an analogous dotted pattern in discrete peri-vascular, non-endothelial, cells in the brain of COVID-19 patients ( Fig. 2C and Supplementary Fig. 2C ).

Reassuringly, the peri-vascular staining pattern was absent from brain samples of non-infected individuals. Together with our observations of ACE2 expression in pericytes, our conclusive localization of viral dsRNA suggests that brain pericytes are indeed uniquely susceptible to viral infection and may serve as CNS entry points for SARS-CoV-2.

We hypothesized that infection of pericytes would result in neuro-inflammation and therefore implemented a spatial immunophenotyping approach for the concomitant detection of the endothelium (CD34 + ) and five immune cell populations, including T helper and cytotoxic T lymphocytes, regulatory T cells, B cells, and macrophages. Surrounding the brain vasculature in COVID-19 patients, we detected CD4 + and CD8 + T cells, as well as CD68 + macrophages, indicative of peri-vascular inflammation, rather than widespread neuroinflammation in the brain parenchyme ( Fig. 2D and Supplementary Fig. 2D ). The immune infiltration did not affect all blood vessels, indicating that the inflammation was not the result of systemic mediators, but rather of local instigation.

Next, we investigated whether impaired pericyte function consequential to SARS-CoV-2 infection and the peri-vascular inflammation impinged on the integrity of the vascular wall.

We first performed a 7-plex mIHC staining focusing on the permeability of the neurovascular unit. Remarkably, in COVID-19 patients, extra-vascular fibrinogen was readily detected as a characteristic gradient in subsets of vessels, occasionally also characterized by ACE2 expression and the presence of viral dsRNA ( Fig. 3A and Supplementary Fig. 3 A and B) .

Conversely, fibrinogen was fully retained within the blood vessels of non-infected control cases. Moreover, astrocyte priming indicative of local activation of the brain parenchyme was not apparent during COVID-19 infection (Fig. 3B and Supplementary Fig. 3C ). Together with our identification of SARS-CoV-2 and immune cell infiltrates in the peri-vascular region, the leakage of fibrinogen from the blood vessels strongly suggests that viral infection of pericytes breaches the tightly organized BBB.

Our findings led us to speculate that the homeostatic state of brain pericytes would be disrupted in COVID-19 patients. Therefore, we collected CSF from an additional eight patients with acute COVID-19 that presented with neurological manifestations, as well as non-infected matched controls (Supplementary Table 2) . Intriguingly, the level of the pericyte marker sPDGFRβ in the CSF of COVID-19 patients was on average significantly lower than in non-COVID-19 control individuals as measured by ELISA, indicative of a perturbed pericyte homeostasis (Fig. 3C ).

The primary cellular receptor for SARS-CoV-2 entry is ACE2 9 , but the expression pattern of ACE2 in the CNS has not been conclusively resolved. Notably, the few published studies detailing the expression of ACE2 and/or SARS-CoV-2 protein in the CNS lack reliable and appropriate controls, precluding firm conclusions. Here, by means of highly sensitive mIHC and the use of both positive and negative control tissues, we were able to confirm that ACE2 An improved understanding of SARS-CoV-2 neurotropism is urgently needed to guide the clinical management of acute neurological symptoms, as well as to define strategies to prevent post-infectious neurological complications. We propose that a possible entry site of SARS-CoV-2 into the CNS goes through ACE2-expressing pericytes. Interestingly, although overt endothelial cell infection by SARS-CoV-2 does not appear to occur 22 , a recent investigation determined that radiolabeled S1 spike viral protein could be retained on the abluminal side of endothelial cells where it associated with the capillary glycocalyx in mice or further sequestered by the endothelium 32 . It is thus tempting to speculate that this represents one plausible way to expose pericytes to the viral infection. Furthermore, the absence of brain pericytes in mice results in a disrupted BBB associated with wide-spread loss of integrity 33 .

Conversely, sealing of the BBB following thrombolysis after ischemic stroke has been 

Supplementary material is available at Brain online. 

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China

Multiorgan and Renal Tropism of SARS-CoV-2

Extrapulmonary manifestations of COVID

The emerging spectrum of COVID-19 neurology: clinical, radiological and laboratory findings. Brain

Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease

Large-Vessel Stroke as a Presenting Feature of Covid-19 in the Young

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues

Single-cell transcriptomics of 20 mouse organs creates a Tabula Muris

Single-cell RNA sequencing of mouse brain and lung vascular and vessel-associated cell types. Sci Data

Genome-wide atlas of gene expression in the adult mouse brain

Allen Mouse Brain Atlas

CSF evidence of pericyte damage in Alzheimer's disease is associated with markers of blood-brain barrier dysfunction and disease pathology

Differential expression of neuronal ACE2 in transgenic mice with overexpression of the brain reninangiotensin system

Expression of ACE2 in Human Neurons Supports the Neuro-Invasive Potential of COVID-19 Virus

Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis

Lack of Evidence of ACE2 Expression and Replicative Infection by SARSCoV-2 in Human Endothelial Cells

Neuropathology of patients with COVID-19 in Germany: a post-mortem case series

Neuropathological Features of Covid-19

Histopathology and ultrastructural findings of fatal COVID-19 infections in Washington State: a case series

Intrauterine vertical SARS-CoV-2 infection: a case confirming transplacental transmission followed by divergence of the viral genome

Microvascular Injury in the Brains of Patients with Covid-19

COVID-19 neuropathology at

SARS-CoV-2 encephalitis is a cytokine release syndrome: evidences from cerebrospinal fluid analyses

CSF biomarkers in patients with COVID-19 and neurological symptoms: A case series

SARS-CoV-2 Disrupts Splicing, Translation, and Protein Trafficking to Suppress Host Defenses

The S1 protein of SARS-CoV-2 crosses the blood-brain barrier in mice

Pericytes regulate the blood-brain barrier

Randomized assessment of imatinib in patients with acute ischaemic stroke treated with intravenous thrombolysis

Activation of PDGF-CC by tissue plasminogen activator impairs blood-brain barrier integrity during ischemic stroke

We gratefully acknowledge Professor David Gisselsson Nord (Lund University) for provision of placenta tissue specimens, and associate professor Emma Hammarlund (Lund University) for critically reading the manuscript. 

KP is a scientific advisor for Baxter and Pfizer, recipient of research grants from Acceleron Supplementary